Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Commentary|Articles|September 9, 2026
- September 2026
- Volume 92
- Issue 9
Retirement Planning: More Than the Math
Author(s)Tim Ulbrich, PharmD
Fact checked by: Justin Mancini
Pharmacists rethink retirement: use compound growth, start early, and define the life you want—so your savings plan fits your future.
Advertisement
Advertisement
Retirement planning is often framed as a math problem. And to be fair, it is. “How much should I save?” “Am I on track?” “What’s my retirement number?”
Related to this article
Community pharmacies are access points, safe places, and sources of stability when everything else feels uncertain.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Walgreens adds virtual coverage navigation, Medicare GLP-1 Bridge support, and pharmacist follow-up calls as GLP-1 discontinuation remains high.
Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association discusses pharmacists’ role in diabetes and CKD care from ASN Kidney Week 2026
A helpful guide for pharmacists if teas, supplements, or cultural foods are part of a patient's regular routine.
Jai Radhakrishnan, MD, discusses why IgG4-related kidney disease is often missed and what MITIGATE subgroup data presented at ASN Kidney Week 2026 show
Real-world data from ASN Kidney Week show GLP-1 RA users with CKD and obesity had lower rates of kidney failure, death, and heart failure exacerbation.
Advertisement
Advertisement